Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale
Neurocrine Biosciences (NBIX) officer Matthew C. Abernethy filed a Rule 144 notice for the potential sale of 2,311 shares, valued at $361,024.42, on September 14, 2026. The shares are tied to Performance Stock Units.
How this was made
The 30-second read
Why it matters
The filing adds a new data point about insider intent but the modest share count limits material impact.
Market read
Primary insider filing with low materiality; useful for monitoring future share supply but not a catalyst for immediate trading.
What to watch
Potential cumulative effect of multiple insider sales over time or upcoming performance milestones that could amplify the impact.
Background
Rule 144 notices disclose planned sales of restricted or insider-held shares, informing investors of future supply.
Ticker impact
Officer filed a Rule 144 notice to sell 2,311 NBIX shares valued at $361,024.42, with a referenced sale date of Sep 14, 2026.
Minimal short‑term impact; potential slight downward pressure if shares are released on Sep 14, 2026.
The filing is a primary source (SEC filing) but the transaction size is modest relative to market cap, limiting price effect.
Market effects
Limited; biotech sector unlikely to be affected by a single small insider sale.
None; the filing pertains only to NBIX shares listed on NASDAQ.
Negligible; no broader market impact.
Counterpoint
If the insider is signaling lack of confidence, the stock could face heightened scrutiny despite the small size.
Key entities
- CompanyNeurocrine Biosciences Inc.
Biotech firm listed on NASDAQ (ticker NBIX).
- OfficerMatthew C. Abernethy
Company officer filing the Rule 144 notice.
